CoChat
Sign Up
Cited by 185Bipolar Disorder and TreatmentTreatment of Major DepressionElectroconvulsive Therapy Studies

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression

Open access
Grunze, Heinz, Kasper, Siegfried, Goodwin, Guy, Bowden, Charles, Baldwin, David, Licht, Rasmus, Vieta, Eduard, Möller, Hans-Jürgen +1 more·2002·The World Journal of Biological Psychiatry
DOI 10.3109/15622970209150612
Open this paper in CoChat — free accountOpen PDF

Abstract

These practice guidelines for the biological, mainly pharmacological treatment of bipolar depression were developed by an international task force of the World Federation of Societies of Biological Psychiatry (WFSBP). Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of bipolar depression. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, and from recent proceedings of key conferences and various national and international treatment guidelines. Their scientific rigor was categorised into four levels of evidence (A-D). As these guidelines are intended for clinical use, the scientific evidence was not only graded, but also commented on by the experts of the task force to ensure practicability.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/15622970209150612

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Atypical antipsychotics have not traditionally been considered a major option in depression guidelines unless psychotic features were present during the acute depressive episode.

    “Atypical antipsychotics have not traditionally been considered as a major option in depression guidelines, unless psychotic features were present during the acute depressive episode”

    From Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis (2010) · cites this paper as Grunze et al. 2002

    The Recommendations (page unavailable) discuss atypical-antipsychotic augmentation in the context of severe and psychotic depression, while the Conclusions identify a mood stabiliser plus antidepressant as the emerging first-line approach. But the paper does not establish a historical rule across depression guidelines that atypical antipsychotics were a major option only when psychotic features were present; it also notes possible antidepressant effects from atypicals themselves. (LLM, conf=0.80)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. Abrams R (1 992) Electroconvulsive therapy. 2nd ed. Oxford University Press, Oxford.
  2. Akiskal H, Pinto 0 (1999) The evolving bipolar spectrum. Proto- types 1, 11, 111, and IV. In: Bipolarity: Beyond classic mania. Akiskal, H (Guest ed) The psychiatric clinics of North America (Bewick, CA, ed), Vol 5, No 3, W.B. Saunders, Philadelphia, pp 51 7-534.
  3. Altshuler L, Suppes T, Black D, Nolen W, Keck PE, Frye M, McElroy SL, Kupka R, Grunze H, Walden J, Leverich G, Denicoff K, Post R (In Press) Impact of antidepressant discontinuation after acute remission from bipolar depression on rates of depressive relapse on one-year follow-up. Am J Psychiatry. American Psychiatric Association (1 994) Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am I Psychiatry 151: 1-36.
  4. Furukawa TA, Streiner DL, Young LT (2002) Antidepressant and benzodiazepine for major depression (Cochrane Review). Cochrane Database Syst Rev CDOOl026.
  5. Emrich HE, Okuma T, Muller AA (eds) Anticonvulsants in affective disorders. Elsevier Science Publishers, Amsterdam, Oxford, Princeton: pp 33-44.
  6. Emrich HM, Okuma T, Muller AA (eds) Anticonvulsants in affective disorders. Elsevier Science, Amsterdam, pp 160-1 66.
  7. Nolen W, Bloemkolk D (2000) Treatment of bipolar depression, a review of the literature and a suggestion for an algorithm. Neuropsychobiology 42 (Suppl 1): 11 -1 7.
  8. Post R, Leverich G, Nolen W, Kupka R, Altshuler L, Frye M, Suppes T, McElroy SL, Keck PE, Crunze H, Walden J (In Press) A reevaluation of the role of antidepressants in the treatment of bipolar depression: Data from the Stanley Bipolar Treatment Network. Bipolar disorders.

Cited by

Sorted by citations

Authors
Grunze, H., Kasper, S., Goodwin, G., Bowden, C., Baldwin, D., Licht, R., Vieta, E., Möller, H.-J., & WFSBP Task Force on Treatment Guide
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • University of Vienna (AT)
  • Warneford Hospital (GB)
  • The University of Texas at San Antonio Health Science Center (US)
  • Royal South Hants Hospital (GB)
  • Aarhus University (DK)
  • Hospital Clínic de Barcelona (ES)
Corresponding author
Grunze, Heinz
ORCID
Venue
The World Journal of Biological Psychiatry
Publisher
Informa UK Limited
Published
2002-01
Volume
3
Issue
3
Pages
115-124
ISSN
  • 1562-2975 (ISSN-L)
  • 1814-1412
DOI
10.3109/15622970209150612
OpenAlex
W2120383646
Cited by
185
References
4
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 1 · 2017: 1 · 2016: 7 · 2015: 6 · 2014: 4 · 2013: 8 · 2012: 12
FWCI
7.18
Type
journal article
Language
en
Open access
Locations
  • The World Journal of Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
bipolar depression, bipolar disorder, pharmacotherapy, biological treatment, antidepressants, mood stabilizers, treatment guidelines, level of evidence
MeSH terms
Lamotrigine, Antidepressive Agents, Biological Psychiatry, Bipolar Disorder, Carbamazepine, Electroconvulsive Therapy, Humans, International Cooperation, Triazines, Valproic Acid, Lithium Carbonate, Antimanic Agents, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review